1.Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
Takeshi CHIDA ; Kazuhito KAWATA ; Kazuyoshi OHTA ; Erika MATSUNAGA ; Jun ITO ; Shin SHIMOYAMA ; Satoru YAMAZAKI ; Hidenao NORITAKE ; Tetsuro SUZUKI ; Takafumi SUDA ; Yoshimasa KOBAYASHI
Gut and Liver 2018;12(2):201-207
BACKGROUND/AIMS: Changes in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years. However, the clinical aspects of disturbed lipid metabolism in chronic HCV infection have not been fully elucidated. METHODS: Dynamic changes in serum total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and apolipoprotein levels in patients infected with HCV genotype 1b were examined during combination therapy with daclatasvir (DCV) and asunaprevir (ASV). RESULTS: Total, LDL−, and HDL-cholesterol levels increased rapidly and persistently after week 4. Apolipoprotein (apo) A-I, apo B, apo C-II, and apo C-III levels were significantly higher at week 4 than at week 0. In contrast, apo A-II and apo E levels were significantly lower. The differences in LDL− and HDL-cholesterol levels were positively correlated with those of apo B and apo A-I, respectively. Interestingly, in patients with non-sustained virological response, these cholesterol levels decreased rapidly after viral breakthrough or viral relapse. Furthermore, similar changes were observed for apo A-I, apo B and apo C-III levels. CONCLUSIONS: Clearance of HCV using combination therapy with DCV and ASV results in rapid changes in serum lipid profiles, suggesting an influence of HCV infection on disturbed lipid metabolism.
Apolipoprotein A-I
;
Apolipoprotein A-II
;
Apolipoprotein C-II
;
Apolipoprotein C-III
;
Apolipoproteins
;
Apolipoproteins B
;
Apolipoproteins E
;
Cholesterol
;
Genotype
;
Hepacivirus*
;
Hepatitis C*
;
Hepatitis*
;
Humans
;
Lipid Metabolism
;
Lipoproteins
;
Recurrence